No Data
No Data
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology's NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer With a HER2 Mutation
Express News | Puma Biotechnology’s Nerlynx® Included in Nccn Clinical Practice Guidelines for the Treatment of Cervical Cancer With a Her2 Mutation
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Express News | Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?